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in the last years increasing attention has been given to the connection between genotype/phenotype 
and cardiovascular events in subjects with familial hypercholesterolemia (fH). MicroRnAs (miRs) bound 
to high-density lipoprotein (HDL) may contribute to better discriminate the cardiovascular risk of fH 
subjects. our aim was to evaluate the HDL-miR panel in heterozygous fH (HefH) patients with an LDLR 
null or defective mutation and its association with pulse wave velocity (pWV). We evaluated lipid panel, 
HDL-miR panel and PWV in 32 LDLR null mutation (LDLR-null group) and 35 LDLR defective variant 
(LDLR-defective group) HeFH patients. HDL-miR-486 and HDL-miR-92a levels were more expressed in 
the LDLR-null group than the LDLR-defective group. When we further stratified the study population 
into three groups according to both the LDLR genotype and history of AScVD (LDLR-null/not-AScVD, 
LDLR-defective/not-AScVD and LDLR/AScVD groups), both the LDLR/AScVD and the LDLR-null/not-
ASCVD groups had a higher expression of HDL-miR-486 and HDL-miR-92a than the LDLR-defective/
not-ASCVD group. Finally, HDL-miR-486 and HDL-miR-92a were independently associated with PWV. 
In conclusion, the LDLR-null group exhibited HDL-miR-486 and HDL-miR-92a levels more expressed 
than the LDLR-defective group. further studies are needed to evaluate these HDL-miRs as predictive 
biomarkers of cardiovascular events in fH.
Atherosclerotic process is a progressive inflammatory disease caused by several external and hereditary factors1. 
Of these, the alterations of lipid and glucose metabolism play a key role in the pathogenesis and progression of 
atherosclerotic cardiovascular disease (ASCVD)2,3. In particular, an increase of the low-density-lipoprotein (LDL) 
cholesterol plasma level is causatively associated with ASCVD4. Despite changes in lifestyle and lipid lowering 
therapies, ASCVD is considered the principal condition of reduced quality-adjusted life years and death5. Thus, 
other mechanisms are involved in atherosclerosis in addition to LDL cholesterol.
Of note, in the last few years several studies have shown an important role of microRNAs (miRs) in the patho-
physiology of atherosclerosis6. MiRs are a class of small noncoding RNAs that inhibit gene expression through 
the alteration of messenger RNA after transcriptional process into the cell7. Not all mature miRs are developed in 
the cell; thus, extracellular miRs such as plasmatic miRs may serve as intercellular messenger8. Many biological 
functions have been attributed to miRs; as concerns the metabolic pathways, they seemed to act as modulators of 
lipid metabolism, and transport and sustained inflammatory diseases9,10. In subjects characterized by high levels 
of LDL cholesterol such as familial hypercholesterolemia (FH), several studies demonstrated that a number of 
circulating miRs were upregulated from childhood, confirming their role in cholesterol homeostasis also in lipid 
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genetic disorders11,12. To avoid plasmatic ribonucleases, miRs are transported by several carriers; in this context, 
the most crucial and stable transporters of miRs are plasmatic lipoproteins, especially the high-density lipopro-
tein (HDL) particles13.
Interestingly, Vickers et al. found that the HDL-miR panel was significantly different between homozygous 
familial hypercholesterolemia and normal subjects14.
In the last few years increasing attention has been given to the connection between genotype/phenotype 
and ASCVD in familial hypercholesterolemia15–17. In particular, several studies have shown that heterozygous 
FH (HeFH) subjects with an LDL receptor (LDLR) null mutation had an increased atherosclerotic burden with 
respect to HeFH subjects with an LDLR defective variant18,19. In this context, it may be helpful to evaluate the 
HDL-miR panel in HeFH subjects with a different LDLR genotype.
To better describe the link between HDL-miRs and HeFH genotype, in this study we aimed to investigate 
the plasma levels of several HDL-miRs correlated with lipid homeostasis and atherosclerotic pathway (miR-486, 
miR-92a, miR-24, miR-223, miR-625*, miR-122)20,21 in HeFH subjects with an LDLR null or defective mutation. 
Moreover, we evaluated the association of HDL-miRs with pulse wave velocity (PWV), an instrumental parame-
ter of early atherosclerosis largely utilized in clinical practice for cardiovascular risk assessment22.
Results
In total, 138 FH patients were assessed and 67 LDLR HeFH patients satisfied the inclusion criteria and were 
involved in the study (Fig. 1). Partecipants were divided in two groups according to the LDLR genotype: 32 HeFH 
patients with an LDLR null mutation (LDLR-null group) and 35 HeFH patients with an LDLR defective mutation 
(LDLR-defective group).
The pretreatment lipid parameters of partecipants are displayed in Table 1. Of corse, the LDLR-null group had 
higher levels of total, LDL and non-HDL cholesterol than the LDLR-defective group.
The general features of partecipants are showed in Table 2. No discrepancy of metabolic parameters were 
showed in the two groups. Moreover, the values of systolic and diastolic BP and the percentage of smokers were 
the same in the LDLR-null and LDLR-defective groups. Furthermore, hs-CRP values were similar between the 
two groups. About medication, the LDLR-null group had a more protracted period of statin therapy than the 
LDLR-defective group (9.5 [2.5–17.5] vs 8 [1.5–12] years, p < 0.05). Furthermore, the majority of patients on 
ezetimibe were in the LDLR-null group than the LDLR-defective group (65.6% vs 40.0%, p < 0.05). Finally, similar 
proportions of antihypertensive medication were found between the two groups. In consideration of intensity of 
statin therapy, no subjects were on low-intensity statins. While a greater number of subjects on moderate-intensity 
statin were in the LDLR-defective group, the percentage of patients on high-intensity statin was more present in 
the LDLR-null group than the LDLR-defective group (75.0% vs 28.6%, p < 0.05). Moreover, the LDLR-null group 
had a greater PWV compared with the LDLR-defective group (9.58 ± 0.92 vs 7.41 ± 0.83 m/s, p < 0.05).
Figure 2 reports the evaluation of HDL-miR panel in the two groups. While the level of HDL-miR-122 
was similar between the two groups, a different expression of HDL-miR-486, HDL-miR-92a, HDL-miR-24, 
HDL-miR-223 and HDL-miR-625* was found between the two groups. In particular, HDL-miR-486 and 
HDL-miR-92a levels were largely represented in the LDLR-null group than the LDLR-defective group 
Figure 1. Enrollment of the Study Population. FH = familial hypercholesterolemia, HeFH = heterozygous 
familial hypercholesterolemia, LDLR = low-density lipoprotein receptor, ApoB = apolipoprotein B, 
PCSK9 = proprotein convertase subtilisin/kexin type 9, ApoE = apolipoprotein E, STAP1 = signal transducing 
adaptor family member 1.
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(HDL-miR-486 and HDL-miR-92a fold change +2.4 for both, p < 0.001 for both, Fig. 2A,B). Moreover, to com-
pare the HDL-miR panel in FH patients with or without cardiovascular events, we performed another analysis 
and stratified the study population into three new groups according to both the LDLR genotype and history of 
ASCVD: LDLR-null/not-ASCVD group (20 FH patients), LDLR-defective/not-ASCVD group (26 FH patients) 
and LDLR/ASCVD group (21 FH patients) (Fig. 3).
Both the LDLR/ASCVD group and the LDLR-null/not-ASCVD group had a higher expression of 
HDL-miR-486 and HDL-miR-92a than the LDLR-defective/not-ASCVD group (for LDLR/ASCVD vs 
LDLR-defective/not-ASCVD group HDL-miR-486 and HDL-miR-92a fold change +2.0 and +2.1 respec-
tively, p < 0.05 for both; for LDLR-null/not-ASCVD vs LDLR-defective/not-ASCVD group HDL-miR-486 and 
HDL-miR-92a fold change +1.7 and +1.8 respectively, p < 0.05 for both, Fig. 3A,B). Moreover, no difference of 
HDL-miR panel was found between LDLR/ASCVD and LDLR-null/not-ASCVD groups.
In the simple regression analysis, HDL-miR-92a and HDL-miR-486 were associated with PWV (r = 0.29, 
p < 0.01 for HDL-miR-92a and r = 0.27, p < 0.05 for HDL-miR-486). Subsequently, in the multiple regression 
analysis including these two HDL-miRs reaching significance and several cardiovascular risk factors as inde-
pendent variables, both HDL-miR-92a and HDL-miR-486 remained significantly associated with PWV (p < 0.01 
for both) (Table 3).
Discussion
The improved evaluation of genotype and phenotype of FH have recently focused on the impact of novel cardio-
vascular risk biomarkers in FH subjects23,24. In this study, we examined the role of HDL-miRs in HeFH subjects 
with an LDLR null or defective mutation; to our learning, no other studies explored HDL-miR panel in these FH 
subgroups. We showed that HDL-miR-486 and HDL-miR-92a were more expressed in the LDLR-null group than 
the LDLR-defective group; moreover, we found that both the LDLR-ASCVD group and the LDLR-null group had 
significant HDL-miR-486 and HDL-miR-92a levels compared with the LDLR-defective group. Finally, we showed 
a significant association between HDL-miR-486, HDL-miR-92a and PWV. Our findings are in line with previous 
studies showing a possible role of these two miRs in lipid homeostasis and the atherosclerotic process; in fact, Liu 
D. et al. found that miR-486 promoted cholesterol concentration in macrophage-derived foam cells25. Moreover, 
Zhang et al. showed that miR-486 was higher in patients with acute myocardial infarction than controls26. Liu F. 
et al. found that also miR-92a was higher in patients with coronary artery disease than controls27; furthermore, 
several studies showed the possible role of miR-92a in the atherosclerotic process by the promoting endothelial 
dysfunction and apoptosis in cardiomyocytes28–30. In line with these findings, Niculescu et al. found that miR-
486 and miR-92a levels in HDL subfractions may identify subjects at increased risk of recurrent cardiovascular 
events31; moreover, they showed that the inhibition of miR-486 and miR-92a decreased liver and plasma cho-
lesterol levels by restoring the lipid metabolism liver genes such as ATP binding cassette subfamily G member 4 
(ABCG4) and the sterol regulatory element binding transcription factor-1 (SREBF1)32. In this context, miR-486 
and miR-92a linked to HDL may be important modulators of HDL functions such as cholesterol efflux, endothe-
lial nitric oxide synthase (eNOS) and nitric oxide (NO) production33.
FH patients are characterized by an increased risk of cardiovascular events34; however, ASCVD risk is not 
the same in FH population. In particular, several studies demonstrated that HeFH patients with an LDLR null 
mutation had a greater atherosclerotic burden than the HeFH patients with an LDLR defective variant18,19,35; this 
is probably due to the higher cholesterol burden of LDLR null HeFH compared with LDLR defective HeFH. In 
our study, all FH patients were on statin therapy and lipid values were similar between the two groups. It is well 
known that statin treatment has significantly reduced the risk of ASCVD in FH subjects36,37. However, despite 
statin therapy, the LDLR null HeFH patients have a higher ASCVD risk compared with the LDLR defective HeFH 
patients on statin therapy38. In line with this consideration, in our study we found that the LDLR null HeFH 
patients had a higher PWV than the LDLR defective HeFH patients. Moreover, in our population we showed a 
direct association of HDL-miR-486 and HDL-miR-92a with PWV; thus, these miRs may support the increase 
of cardiovascular risk and the advance of atherosclerosis in addition to LDL cholesterol burden in FH patients.
Recent clinical trials where increased levels of HDL cholesterol have been obtained, failed to demonstrated 
a significant reduction of ASCVD in a large population at high cardiovascular risk39,40. These findings strongly 
support the hypothesis of “HDL quality” and not HDL quantity. Several studies have focused on the alterations 
of HDL quality in FH subjects, and, in particular, on their decreased ability to support cholesterol efflux from 
macrophages, and on their diminished anti-inflammatory and anti-oxidant properties41–43. In this context, miRs 
bound to HDL particles may effectively modulate their function on lipid metabolism and the atherosclerotic 
LDLR-null group
(n = 32)
LDLR-defective group
(n = 35)
p Value between 
two groups
Pretreated Lipid Values
Total cholesterol, mg/dL 387.62 ± 28.98 336.13 ± 29.44 <0.01
HDL cholesterol, mg/dL 51.58 ± 10.49 52.3 ± 11.23 0.85
Triglycerides, mg/dL 95.5 (71.5–150) 97.5 (71.75–150) 0.81
LDL cholesterol, mg/dL 282.32 ± 23.87 233.28 ± 22.43 <0.01
Non-HDL cholesterol, mg/dL 316.19 ± 37.92 265.83 ± 38.38 <0.01
Table 1. Pretreatment lipid values of the Study Population. Data are presented as mean ± standard deviation 
or median (interquartile range). HDL = high-density lipoprotein, LDL = low-density lipoprotein, LDLR = low-
density lipoprotein receptor.
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process. Recently, several studies have focused attention on miRs as possible targets in FH patients33,44. However, 
no prospective studies have shown if HDL-miR-486 and HDL-miR-92a could be good predictors for subsequent 
cardiovascular events in FH subjects; thus, additional studies are required to investigate their role in the progres-
sion of the atherosclerotic burden and their possible relationship with ASCVD in a large FH population.
There are several limitations to our study. First, we are unable to establish a causal relationship and tempo-
rality between HDL-miR-486 and HDL-miR-92a and possible changes in PWV by the cross-sectional design of 
this study. The number of studied patients was relatively small; however, we showed a significant difference of 
HDL-miR panel in the groups and an independent association of HDL-miR-486, HDL-miR-92a and PWV was 
found. Finally, other cardiovascular parameters such as cholesterol burden were not available and, thus, were not 
taken into consideration.
In conclusion, HDL-miR-486 and HDL-miR-92a levels were more expressed in the LDLR-null group than 
the LDLR-defective group; moreover, HDL-miR-486 and HDL-miR-92a were significantly associated with PWV. 
Our study suggests that these miRs may be helpful to improve cardiovascular risk stratification; additional studies 
are required to investigate HDL-miRs as predictive biomarkers of cardiovascular events and possible treatment 
targets in FH patients.
LDLR-null group
(n = 32)
LDLR-defective
group
(n = 35)
p Value
between
two groups
Demographic Characteristics
N 32 35
Age, years 48.69 ± 14.36 51.97 ± 15.47 0.37
Men, n (%) 18 (56.3) 19 (54.3) 0.61
Body mass index, kg/m2 25.21 ± 3.34 25.38 ± 3.79 0.84
ASCVD, n (%) 12 (37.5) 9 (25.7) 0.33
Glucose Values
FPG, mg/dL 85.7 ± 6.84 88.11 ± 6.32 0.14
HbA1c, % 5.42 ± 0.29 5.51 ± 0.28 0.25
Lipid Values
Total cholesterol, mg/dL 188.65 ± 25.26 186.5 ± 24.31 0.86
HDL cholesterol, mg/dL 49.16 ± 10.62 52.81 ± 8.84 0.07
Triglycerides, mg/dL 87 (80–117) 88.5 (81–119) 0.76
LDL cholesterol, mg/dL 121.54 ± 21.46 116.33 ± 20.48 0.31
Non-HDL cholesterol, mg/dL 140.48 ± 22.04 135.69 ± 22.07 0.16
ApoB, mg/dL 116.79 ± 25.02 110.53 ± 24.71 0.11
ApoAI, m g/dL 133.71 ± 23.34 137.62 ± 23.31 0.29
ApoB to ApoAI ratio 0.88 ± 0.34 0.81 ± 0.31 0.06
Lp(a), nmol/L 20.8 (10.05–62.95) 19.2 (9.69–41.05) 0.45
Risk Factors
Systolic BP, mmHg 118.55 ± 9.33 119.17 ± 13.37 0.83
Diastolic BP, mmHg 70.48 ± 7.78 71.36 ± 9.17 0.28
Smoking, n (%) 10 (31.3) 13 (37.1) 0.61
hs-CRP, mg/dL 0.10 (0.05–0.19) 0.09 (0.04–0.15) 0.39
Treatment
Duration of Statin therapy, years 9.5 (2.5–17.5) 8 (1.5–12) <0.05
Ezetimibe, n (%) 21 (65.6) 14 (40.0) <0.05
Antihypertensive therapy, n(%) 11 (34.4) 13 (37.1) 0.81
Intensity of Statin Therapy
Low, n (%) — — —
Moderate, n (%) 8 (25.0) 25 (71.4) <0.05
High, n (%) 24 (75.0) 10 (28.6) <0.05
Early atherosclerotic biomarker
PWV, m/s 9.58 ± 0.92 7.41 ± 0.83 <0.05
Table 2. Characteristics of the Study Population. Data are presented as mean ± standard deviation, 
percentages, or median (interquartile range). ASCVD = atherosclerotic cardiovascular disease, FPG = fasting 
plasma glucose, HbA1c = glycated hemoglobin, HDL = high-density lipoprotein, LDL = low-density 
lipoprotein, LDLR = low-density lipoprotein receptor, ApoB = apolipoprotein B, ApoAI = apolipoprotein AI, 
Lp(a) = lipoprotein (a), BP = blood pressure, hs-CRP = high sensitivity C-reactive protein, PWV = pulse wave 
velocity.
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Methods
Study design and population. It was an observational study in subjects with a diagnosis of FH already 
confirmed by genetic evaluation45,46. The patients were evaluated from the University Hospital of Catania and 
the Dyslipidemia Center of the Niguarda Hospital in Milan, Italy, two tertiary lipid centers, from April 2017 to 
December 201816. The age of partecipants were over 18 and under 70 years and assumed statin therapy at the 
moment of the study. In particular, we only included FH patients with a null or defective LDLR genetic variant; 
the reason of this restricted criteria was that LDLR mutations were associated with several genotype/phenotype 
patterns that could contribute to the heterogeneity of FH population. In this context, we aimed to evaluate possi-
ble novel cardiovascular biomarkers such as HDL-miRs in these subjects.
The study was accepted by the local ethics committees Catania 2 and Milano Area 3 in accordance with the 
ethical standards of the institutional and national research committees and with the 1964 Declaration of Helsinki 
and its later amendments or comparable ethical standards. Informed consent was attained from all partecipants 
the study.
All subjects obtained a physical examination and clinical biochemistry parameters measured as previously 
described2. Anthropometric parameters, glycemic status, arterial pressure, medications, ASCVD, advanced renal 
Figure 2. HDL-miR panel in the LDLR-null and the LDLR-defective groups. *p value < 0.05 versus LDLR-
defective group, #p value < 0.001 versus LDLR-defective group. To test differences of HDL-miR −ΔCt values in 
the two groups, Student’s t test was used.
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disease and smoking abits were defined as previously described22,47,48. The severity of liver disease was defined as 
previously described49. The exclusion criteria were defined as previously described22.
Biochemical analysis. Fasting plasma glucose (FPG), serum total cholesterol, TG, high-density lipoprotein 
(HDL) cholesterol, hs-CRP, Apolipoprotein B (ApoB), Apolipoprotein A1 (ApoA1) were assessed as previously 
Figure 3. HDL-miR panel in the LDLR-null/not-ASCVD, LDLR-defective/not-ASCVD and the LDLR/ASCVD 
groups. *p value < 0.05 versus LDLR-defective/not-ASCVD group. To test differences of HDL-miR −ΔCt 
values in the two groups, Student’s t test was used.
Independent Variables Coefficient β p Value
Model*
HDL-miR-92a, −ΔCt 0.343 <0.01
HDL-miR-486, −ΔCt 0.308 <0.01
Table 3. Multiple regression analysis evaluating PWV as dependent variable. *Model was adjusted for age, sex, 
smoking status, systolic blood pressure, LDL cholesterol and glycated hemoglobin.
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described50. Levels of lipoprotein (a) [Lp(a)] were measured as previously described22. LDL cholesterol was 
obtained by the Friedewald formula. Glycated hemoglobin (HbA1c) was measured as previously described51.
HDL purification. HDL particles (d = 1.063–1.21 g/mL) were obtained by sequential ultracentrifugation 
from plasma collected from all subjects. After separation, HDL particles were dialyzed against sterilized PBS to 
remove the high-salt KBr solutions and immediately frozen at −80 °C until use52. By using ExoTEST Ready to Use 
Kit for ELISA Exosome quantification (Hansa BioMed), we assessed that the purified HDL particles were negative 
for the classic exosomal protein marker CD9.
RNA extraction. HDL-carried miRs were extracted from 400 μl of purified HDL particles as previously 
described53.
Single taqMan assays. MiR expression levels were evaluated by Single TaqMan MicroRNA Assays as pre-
viously described53.
pulse wave velocity evaluation. PWV was performed as previously described54.
Statistical analysis. The Kolmogorov-Smirnov test was used to assess normality distribution of all variables. 
Continuous parametric and non parametric data are described as mean ± standard deviation (SD) or median 
(interquartile range-IQR), respectively; moreover, categorical variables are reported as frequency (percentage) 
and evaluated by χ2 test. Continuous non-parametric variables (TG, Lpa, duration of statin therapy and hs-CRP) 
were logarithmically transformed for statistical analysis to diminish dissymetry. MiR expression data are pre-
sented as minus Delta Ct values (−ΔCt), calculated according to the following formula: −1*(Threshold Cycle of 
analysed miRNA − Threshold Cycle of U6 in each sample). MiR expression Fold Changes (FC) were calculated by 
applying the 2−ΔΔCT method by using small nuclear RNA U6 as reference gene. Student’s t test was performed for 
clinical and biochemical characteristics. Simple regression analysis was used to evaluate the relation of HDL-miRs 
with PWV. Subsequently, to analyze a possible independent association with changes of PWV, HDL-miRs reach-
ing significance were included in a multivariate analysis with principal cardiovascular risk factors (age, sex, smok-
ing, systolic BP, HbA1c, and LDL cholesterol). The variance inflation factor (VIF) was performed to assess the 
problem of multicollinearity in multivariate analysis. All statistical analyses were obtained by IBM SPSS Statistics 
for Windows version 23. For all tests, p < 0.05 was considered significant.
ethical approval. This study was approved by the local ethics committee in accordance with the ethical 
standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and 
its later amendments or comparable ethical standards. This article does not contain any studies with animals 
performed by any of the authors.
informed consent. Informed consent was obtained from each participant enrolled in the study.
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